Tp53 Mutation News Today

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center presented phase 2 results for 25 patients with TP53 mutations.